Atossa Therapeutics, Inc. To Acquire Stake In Privately Held Dynamic Cell Therapies As Part Of Overall Car-T Strategy
Acquiring Company
Atossa Therapeutics
Acquired Company
Dynamic Cell Therapies
SeattleBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareMedicalTherapeuticsDescription
Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments.
Quick answer
Atossa Therapeutics is acquiring Dynamic Cell Therapies, announced November 1, 2022. Atossa Therapeutics is based in Seattle, Washington, United States.
- How much did Atossa Therapeutics pay for Dynamic Cell Therapies?
- The deal value was not disclosed.
- What does Atossa Therapeutics do?
- Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
- Where are Atossa Therapeutics and Dynamic Cell Therapies based?
- Atossa Therapeutics is based in Seattle, Washington, United States.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Pharmaceutical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Sonic Healthcare Acquires Strategic Stake In Microba Life Sciences, Establishes Significant Commercial Partnership (November 29, 2022)
- Pfizer Completes Acquisition Of Global Blood Therapeutics (October 5, 2022)
- Pfizer Completes Acquisition Of Biohaven Pharmaceuticals (October 3, 2022)
- Sumitovant Biopharma And Sumitomo Pharma Announce Offer To Acquire Outstanding Shares Of Myovant Sciences (October 2, 2022)
- Lilly Completes Acquisition Of Akouos Expanding Efforts To Help People With Genetic Diseases (December 1, 2022)
- Lilly To Acquire Akouos To Discover And Develop Treatments For Hearing Loss (October 18, 2022)
Who to call at Atossa Therapeutics, and when
When Atossa Therapeutics changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Atossa Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Atossa Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Atossa Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Atossa Therapeutics makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Dynamic Cell Therapies?
Dynamic Cell Therapies was acquired by Atossa Therapeutics, based in Seattle. The deal was reported on November 1, 2022. Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Atossa Therapeutics is publicly traded (ATOS) and operates in Biotechnology.
When did Atossa Therapeutics acquire Dynamic Cell Therapies?
Atossa Therapeutics's acquisition of Dynamic Cell Therapies was reported on November 1, 2022. Atossa Therapeutics, Inc. (Nasdaq: ATOS), announces today that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT). Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Dynamic Cell Therapies do?
Dynamic Cell Therapies is venture capital backed and based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. It is privately held, operating in Biotechnology.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.